StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
MAIABullishIndustry Newsnews
High materiality8/10

MAIA completes THIO-101 Part C enrollment with Fast Track for NSCLC

Jun 25, 2026, 8:12 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive enrollment milestone and Fast Track designation can reduce regulatory risk and attract interest in MAIA’s value proposition, especially given prior OS signals; catalysts may drive upside if follow-on data align with expectations.

AI summary

What happened, with direct paths to the underlying reporting

MAIA announced international Part C enrollment completion for THIO-101 in 3L NSCLC, with 41 patients across six countries and ongoing US screening. The FDA granted Fast Track designation for ateganosine, potentially expediting regulatory review. Prior THIO-101 data showed a median OS of 17.8 months and durable long survivors, underscoring potential upside if the current trial data mature favorably.

  • MAIA completes international THIO-101 Part C enrollment; 41 patients enrolled.
  • Part C randomizes ateganosine + cemiplimab vs ateganosine alone for 3L NSCLC.
  • FDA Fast Track designation granted for ateganosine in NSCLC.
  • THIO-101 Parts A/B show 17.8-month median OS; 8 patients >2 years.
  • Three US sites activated; international enrollment completed.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event